URGN logo

UroGen Pharma Ltd. (URGN) EBITDA

Annual EBITDA:

-$110.33M-$28.43M(-34.71%)
December 31, 2024

Summary

  • As of today, URGN annual EBITDA is -$110.33 million, with the most recent change of -$28.43 million (-34.71%) on December 31, 2024.
  • During the last 3 years, URGN annual EBITDA has fallen by -$2.74 million (-2.54%).
  • URGN annual EBITDA is now -11013.45% below its all-time high of $1.01 million, reached on December 31, 2016.

Performance

1-Year Change

-34.71%

3-Year Change

-2.54%

5-Year Change

-2.02%

15-Year Change

-458.86%

URGN EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

15.53%
URGN annual EBITDA is higher than 15.53% of companies in Healthcare sector

Range

All-Time High

$1.01M
URGN annual EBITDA is currently >-9900.00% below its historical high of $1.01 million

3-Year Low

-$110.33M
URGN annual EBITDA is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
URGN previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

Mar 10, 2026
URGN next annual earnings announcement is scheduled for Mar 10, 2026

OtherURGNincome statement metrics

Annual Revenue

$90.40M
URGN annual revenue is $90.40 million

Annual Net Income

-$126.87M
URGN annual net profit is -$126.87 million

Annual EBIT

-$111.52M
URGN annual earnings before interest & taxes is -$111.52 million

Annual EPS

-$2.96
URGN annual earnings per share is -$2.96

Quarterly EBITDA:

-$26.75M+$14.11M(+34.53%)
September 30, 2025

Summary

  • As of today, URGN quarterly EBITDA is -$26.75 million, with the most recent change of +$14.11 million (+34.53%) on September 30, 2025.
  • Over the past year, URGN quarterly EBITDA has dropped by -$9.47 million (-54.79%).
  • URGN quarterly EBITDA is now -291.30% below its all-time high of $13.98 million, reached on December 31, 2016.

Performance

3-Month Change

+34.53%

1-Year Change

-54.79%

3-Year Change

-51.52%

5-Year Change

+6.56%

URGN Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

16.35%
URGN quarterly EBITDA is higher than 16.35% of companies in Healthcare sector

Range

All-Time High

$13.98M
URGN quarterly EBITDA is currently -291.30% below its historical high of $13.98 million

3-Year Low

-$40.85M
URGN quarterly EBITDA is currently +34.53% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2025
URGN previous earnings announcement was published on Sep 30, 2025

Next Quarterly Earnings Report Date

Mar 10, 2026
URGN next earnings announcement is scheduled for Mar 10, 2026

OtherURGNincome statement metrics

Quarterly Revenue

$27.48M
URGN quarterly revenue is $27.48 million

Quarterly Net Income

-$33.35M
URGN quarterly net profit is -$33.35 million

Quarterly EBIT

-$27.39M
URGN quarterly earnings before interest & taxes is -$27.39 million

Quarterly EPS

-$0.69
URGN quarterly earnings per share is -$0.69

TTM EBITDA:

-$131.37M-$9.47M(-7.77%)
September 30, 2025

Summary

  • As of today, URGN TTM EBITDA is -$131.37 million, with the most recent change of -$9.47 million (-7.77%) on September 30, 2025.
  • Over the past year, URGN TTM EBITDA has dropped by -$48.94 million (-59.37%).
  • URGN TTM EBITDA is now -2973.32% below its all-time high of $4.57 million, reached on December 31, 2016.

Performance

3-Month Change

-7.77%

1-Year Change

-59.37%

3-Year Change

-70.93%

5-Year Change

+4.46%

URGN TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

12.85%
URGN TTM EBITDA is higher than 12.85% of companies in Healthcare sector

Range

All-Time High

$4.57M
URGN TTM EBITDA is currently -2973.32% below its historical high of $4.57 million

3-Year Low

-$131.37M
URGN TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2025
URGN previous earnings announcement was published on Sep 30, 2025

Next Quarterly Earnings Report Date

Mar 10, 2026
URGN next earnings announcement is scheduled for Mar 10, 2026

OtherURGNincome statement metrics

TTM Revenue

$96.52M
URGN TTM revenue is $96.52 million

TTM Net Income

-$164.64M
URGN TTM net profit is -$164.64 million

TTM EBIT

-$133.41M
URGN TTM earnings before interest & taxes is -$133.41 million

TTM EPS

-$3.46
URGN TTM earnings per share is -$3.46

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$110.33M
URGN annual EBITDA is -$110.33 million

Annual Net Income

-$126.87M
URGN annual net profit is -$126.87 million

Annual Interest Expense

$0.00
URGN annual interest expense is $0.00

Annual Income Tax

$2.83M
URGN annual income tax is $2.83 million

Annual D&A

$1.19M
URGN annual D&A is $1.19 million

URGN EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-34.7%-54.8%-59.4%
3Y3 Years-2.5%-51.5%-70.9%
5Y5 Years-2.0%+6.6%+4.5%

URGN EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-34.7%at low-104.4%+34.5%-105.8%at low
5Y5-Year-34.7%+11.5%-104.4%+34.5%-105.8%+4.5%
All-TimeAll-Time>-9999.0%+11.5%-291.3%+34.5%-2973.3%+4.5%

URGN EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$26.75M(+34.5%)
-$131.37M(-7.8%)
Jun 2025
-
-$40.85M(-12.2%)
-$121.90M(-14.3%)
Mar 2025
-
-$36.42M(-33.1%)
-$106.62M(-11.5%)
Dec 2024
-$110.33M(-34.7%)
-$27.35M(-58.3%)
-$95.60M(-16.0%)
Sep 2024
-
-$17.28M(+32.4%)
-$82.43M(-5.4%)
Jun 2024
-
-$25.58M(-0.7%)
-$78.23M(-15.7%)
Mar 2024
-
-$25.39M(-79.0%)
-$67.61M(-5.9%)
Dec 2023
-$81.90M(+16.2%)
-$14.19M(-8.4%)
-$63.83M(+8.1%)
Sep 2023
-
-$13.09M(+12.5%)
-$69.48M(+6.2%)
Jun 2023
-
-$14.95M(+30.8%)
-$74.05M(+4.3%)
Mar 2023
-
-$21.61M(-9.0%)
-$77.33M(-0.1%)
Dec 2022
-$97.77M(+9.1%)
-$19.83M(-12.3%)
-$77.22M(-0.5%)
Sep 2022
-
-$17.65M(+3.2%)
-$76.86M(+6.5%)
Jun 2022
-
-$18.24M(+15.2%)
-$82.19M(+4.8%)
Mar 2022
-
-$21.50M(-10.5%)
-$86.33M(+4.6%)
Dec 2021
-$107.60M(+13.7%)
-$19.46M(+15.3%)
-$90.52M(+7.3%)
Sep 2021
-
-$22.99M(-2.7%)
-$97.69M(+5.5%)
Jun 2021
-
-$22.38M(+12.9%)
-$103.33M(+8.0%)
Mar 2021
-
-$25.69M(+3.6%)
-$112.28M(+10.0%)
DateAnnualQuarterlyTTM
Dec 2020
-$124.69M(-15.3%)
-$26.64M(+6.9%)
-$124.69M(+9.3%)
Sep 2020
-
-$28.63M(+8.6%)
-$137.50M(-4.0%)
Jun 2020
-
-$31.32M(+17.8%)
-$132.26M(-6.1%)
Mar 2020
-
-$38.10M(+3.4%)
-$124.63M(-14.5%)
Dec 2019
-$108.15M(-40.9%)
-$39.44M(-68.6%)
-$108.89M(-16.6%)
Sep 2019
-
-$23.39M(+1.3%)
-$93.42M(-2.6%)
Jun 2019
-
-$23.69M(-5.9%)
-$91.06M(-6.2%)
Mar 2019
-
-$22.37M(+6.7%)
-$85.75M(-11.4%)
Dec 2018
-$76.76M(-288.8%)
-$23.97M(-14.0%)
-$76.96M(-22.0%)
Sep 2018
-
-$21.03M(-14.4%)
-$63.10M(-49.0%)
Jun 2018
-
-$18.38M(-35.3%)
-$42.35M(-42.0%)
Mar 2018
-
-$13.58M(-34.5%)
-$29.83M(-51.1%)
Dec 2017
-$19.74M(-2052.8%)
-$10.10M(-3431.5%)
-$19.74M(-555.0%)
Sep 2017
-
-$286.00K(+95.1%)
$4.34M(+403.9%)
Jun 2017
-
-$5.86M(-67.9%)
-$1.43M(-232.3%)
Mar 2017
-
-$3.49M(-125.0%)
$1.08M(-76.4%)
Dec 2016
$1.01M(+108.2%)
$13.98M(+331.0%)
$4.57M(+148.6%)
Sep 2016
-
-$6.05M(-80.3%)
-$9.41M(-180.3%)
Jun 2016
-
-$3.36M
-$3.36M
Dec 2015
-$12.30M
-
-

FAQ

  • What is UroGen Pharma Ltd. annual EBITDA?
  • What is the all-time high annual EBITDA for UroGen Pharma Ltd.?
  • What is UroGen Pharma Ltd. annual EBITDA year-on-year change?
  • What is UroGen Pharma Ltd. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for UroGen Pharma Ltd.?
  • What is UroGen Pharma Ltd. quarterly EBITDA year-on-year change?
  • What is UroGen Pharma Ltd. TTM EBITDA?
  • What is the all-time high TTM EBITDA for UroGen Pharma Ltd.?
  • What is UroGen Pharma Ltd. TTM EBITDA year-on-year change?

What is UroGen Pharma Ltd. annual EBITDA?

The current annual EBITDA of URGN is -$110.33M

What is the all-time high annual EBITDA for UroGen Pharma Ltd.?

UroGen Pharma Ltd. all-time high annual EBITDA is $1.01M

What is UroGen Pharma Ltd. annual EBITDA year-on-year change?

Over the past year, URGN annual EBITDA has changed by -$28.43M (-34.71%)

What is UroGen Pharma Ltd. quarterly EBITDA?

The current quarterly EBITDA of URGN is -$26.75M

What is the all-time high quarterly EBITDA for UroGen Pharma Ltd.?

UroGen Pharma Ltd. all-time high quarterly EBITDA is $13.98M

What is UroGen Pharma Ltd. quarterly EBITDA year-on-year change?

Over the past year, URGN quarterly EBITDA has changed by -$9.47M (-54.79%)

What is UroGen Pharma Ltd. TTM EBITDA?

The current TTM EBITDA of URGN is -$131.37M

What is the all-time high TTM EBITDA for UroGen Pharma Ltd.?

UroGen Pharma Ltd. all-time high TTM EBITDA is $4.57M

What is UroGen Pharma Ltd. TTM EBITDA year-on-year change?

Over the past year, URGN TTM EBITDA has changed by -$48.94M (-59.37%)
On this page